A next-generation positron emission tomography/computed tomography (PET/CT) system, Biograph Vision.X, reportedly offers enhanced spatial resolution and a time of flight of 178 picoseconds.
Biograph Vision.X (Image Credit: Seimens Healthineers)
Offering technological advancements ranging from an accelerated time of flight (TOF) to artificial intelligence (AI)-enabled workflow enhancements, Siemens Healthineers showcased Biograph Vision.X, a new positron emission tomography/computed tomography (PET/CT) system at the 2023 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting, taking place June 24-27 in Chicago.
One of the new system’s benefits is the Optiso Ultra Dynamic Range detector technology, which reportedly provides enhanced spatial resolution through silicon photomultipliers (SiPMs) that facilitate utilization of small (3.2 mm x 3.2 mm) lutetium oxyorthosilicate crystal elements.
Leveraging this technology, the Biograph Vision.X also offers a TOF of 178 picoseconds that bolsters patient throughput and reduces radiation exposure for patients, according to Siemens Healthineers.
“This TOF improvement translates into true increased sensitivity for better imaging performance. This level of precision is more important than ever as more physicians now use PET/CT imaging not only for diagnosis but throughout the patient care cycle – from diagnosis to therapy monitoring to post-therapy follow up,” noted James Williams, Ph.D, the head of Siemens Healthineers Molecular Imaging. “And such precision in PET/CT is invaluable in theranostics, where diagnostic and therapeutic capabilities are combined to help treat post-recurrent prostate cancer patients.”
The company added that the system leverages AIDAN intelligent imaging, an AI platform built on over 700 patented machine- and deep learning applications, to enhance radiology workflow efficiency.
Pending 510(k) clearance from the Food and Drug Administration, the Biograph Vision.X system is not commercially available at this time, according to Siemens Heathineers. The company said the new system will be available as in-field upgrade for physicians who currently utilize the Biograph Vision device.
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
March 18th 2025In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.
Study Shows No Impact of Hormone Therapy on PET/CT with 18F-Piflufolastat in PCa Imaging
May 7th 2025For patients with recurrent or metastatic prostate cancer, new research findings showed no significant difference in the sensitivity of 18F-piflufolastat PET/CT between patients on concurrent hormone therapy and those without hormone therapy.
MRI Study at ARRS Raises Questions About Disparities in Detection of MASLD
May 3rd 2025New research revealed that Hispanic Americans with evidence of hepatic steatosis on MRI but no formal diagnosis of MASLD had over a fourfold higher risk of developing hepatocellular carcinoma in comparison to those who had a formal diagnosis of MASLD.